Cargando…

Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection

We described the long-term decay of neutralizing antibody (NtAb) to the wild-type and Delta SARS-CoV-2 variant after three antigen stimulations (mild or asymptomatic natural infection followed by two doses of the BNT162b2 mRNA vaccine after a median of 296 days) in immunocompetent healthcare workers...

Descripción completa

Detalles Bibliográficos
Autores principales: Vicenti, Ilaria, Basso, Monica, Dragoni, Filippo, Gatti, Francesca, Scaggiante, Renzo, Fiaschi, Lia, Parisi, Saverio G., Zazzi, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025891/
https://www.ncbi.nlm.nih.gov/pubmed/35455329
http://dx.doi.org/10.3390/vaccines10040580
_version_ 1784690987313922048
author Vicenti, Ilaria
Basso, Monica
Dragoni, Filippo
Gatti, Francesca
Scaggiante, Renzo
Fiaschi, Lia
Parisi, Saverio G.
Zazzi, Maurizio
author_facet Vicenti, Ilaria
Basso, Monica
Dragoni, Filippo
Gatti, Francesca
Scaggiante, Renzo
Fiaschi, Lia
Parisi, Saverio G.
Zazzi, Maurizio
author_sort Vicenti, Ilaria
collection PubMed
description We described the long-term decay of neutralizing antibody (NtAb) to the wild-type and Delta SARS-CoV-2 variant after three antigen stimulations (mild or asymptomatic natural infection followed by two doses of the BNT162b2 mRNA vaccine after a median of 296 days) in immunocompetent healthcare workers (HCWs). Live virus microneutralization against the B.1 and Delta SARS-CoV-2 variants was performed in VERO E6 cell cultures. The median NtAb titers for B.1 and Delta were comparable and highly correlated at both 20 and 200 days after the second vaccine dose in the 23 HCWs enrolled (median age, 46 years). A small group of naturally infected unvaccinated HCWs had comparable NtAb titers for the two strains after a median follow-up of 522 days from infection diagnosis. The NtAb response to the Delta VoC appears to follow the same long-term dynamics as the wild-type response regardless of the vaccinal boost; data collected after three antigen stimulations (natural infection followed by two doses of the BNT162b2 mRNA vaccine) may be helpful for tailoring the continuous monitoring of vaccine protection against SARS-CoV-2 variants over time.
format Online
Article
Text
id pubmed-9025891
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90258912022-04-23 Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection Vicenti, Ilaria Basso, Monica Dragoni, Filippo Gatti, Francesca Scaggiante, Renzo Fiaschi, Lia Parisi, Saverio G. Zazzi, Maurizio Vaccines (Basel) Communication We described the long-term decay of neutralizing antibody (NtAb) to the wild-type and Delta SARS-CoV-2 variant after three antigen stimulations (mild or asymptomatic natural infection followed by two doses of the BNT162b2 mRNA vaccine after a median of 296 days) in immunocompetent healthcare workers (HCWs). Live virus microneutralization against the B.1 and Delta SARS-CoV-2 variants was performed in VERO E6 cell cultures. The median NtAb titers for B.1 and Delta were comparable and highly correlated at both 20 and 200 days after the second vaccine dose in the 23 HCWs enrolled (median age, 46 years). A small group of naturally infected unvaccinated HCWs had comparable NtAb titers for the two strains after a median follow-up of 522 days from infection diagnosis. The NtAb response to the Delta VoC appears to follow the same long-term dynamics as the wild-type response regardless of the vaccinal boost; data collected after three antigen stimulations (natural infection followed by two doses of the BNT162b2 mRNA vaccine) may be helpful for tailoring the continuous monitoring of vaccine protection against SARS-CoV-2 variants over time. MDPI 2022-04-09 /pmc/articles/PMC9025891/ /pubmed/35455329 http://dx.doi.org/10.3390/vaccines10040580 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Vicenti, Ilaria
Basso, Monica
Dragoni, Filippo
Gatti, Francesca
Scaggiante, Renzo
Fiaschi, Lia
Parisi, Saverio G.
Zazzi, Maurizio
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection
title Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection
title_full Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection
title_fullStr Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection
title_full_unstemmed Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection
title_short Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection
title_sort comparable post-vaccination decay of neutralizing antibody response to wild-type and delta sars-cov-2 variant in healthcare workers recovered from mild or asymptomatic infection
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025891/
https://www.ncbi.nlm.nih.gov/pubmed/35455329
http://dx.doi.org/10.3390/vaccines10040580
work_keys_str_mv AT vicentiilaria comparablepostvaccinationdecayofneutralizingantibodyresponsetowildtypeanddeltasarscov2variantinhealthcareworkersrecoveredfrommildorasymptomaticinfection
AT bassomonica comparablepostvaccinationdecayofneutralizingantibodyresponsetowildtypeanddeltasarscov2variantinhealthcareworkersrecoveredfrommildorasymptomaticinfection
AT dragonifilippo comparablepostvaccinationdecayofneutralizingantibodyresponsetowildtypeanddeltasarscov2variantinhealthcareworkersrecoveredfrommildorasymptomaticinfection
AT gattifrancesca comparablepostvaccinationdecayofneutralizingantibodyresponsetowildtypeanddeltasarscov2variantinhealthcareworkersrecoveredfrommildorasymptomaticinfection
AT scaggianterenzo comparablepostvaccinationdecayofneutralizingantibodyresponsetowildtypeanddeltasarscov2variantinhealthcareworkersrecoveredfrommildorasymptomaticinfection
AT fiaschilia comparablepostvaccinationdecayofneutralizingantibodyresponsetowildtypeanddeltasarscov2variantinhealthcareworkersrecoveredfrommildorasymptomaticinfection
AT parisisaveriog comparablepostvaccinationdecayofneutralizingantibodyresponsetowildtypeanddeltasarscov2variantinhealthcareworkersrecoveredfrommildorasymptomaticinfection
AT zazzimaurizio comparablepostvaccinationdecayofneutralizingantibodyresponsetowildtypeanddeltasarscov2variantinhealthcareworkersrecoveredfrommildorasymptomaticinfection